Time course of nodal enhancement with CT x-ray nanoparticle contrast agents - Effect of particle size and chemical structure

被引:18
作者
McIntire, GL
Bacon, ER
Illig, KJ
Coffey, SB
Singh, B
Bessin, G
Shore, MT
Wolf, GL
机构
[1] Nycomed Amersham PLC, Wayne, PA USA
[2] Massachusetts Gen Hosp, Ctr Imaging & Pharmaceut Res, Charlestown, MA USA
关键词
lymph node; computed tomography lymphography; nanoparticles; clearance;
D O I
10.1097/00004424-200002000-00001
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
RATIONALE AND OBJECTIVES. Levels of CT enhancement in rabbit lymph nodes were followed with time after subcutaneous injection of four iodinated, insoluble nanoparticle contrast agents to provide experimental support for the hypothesis that clearance of these agents is related to the chemical structure of the agent itself. The impact of particle size was also studied, METHODS. Subcutaneous injections (2 x 0.25 mL) were made in the dorsum of rabbit paws with 15% suspensions of four nanoparticle contrast agents. Images were obtained at 4, 10, 24, 48, and 72 hours and 5, 7, and 14 days after injection. Average attenuation (in Hounsfield units [HU]), node volume, and total iodine uptake were estimated from the CT scans for each lymph node at each time point, RESULTS. All the agents provided adequate enhancement of both the popliteal and axillary lymph nodes of the rabbit (ie, > Delta 100 HU). Lymph node volume appears to be related to the persistence of enhancement, with long-lived agents demonstrating the greatest increase in size. The rate of clearance from the lymph nodes is related to the structure of the agent. CONCLUSIONS. Clearance of insoluble, iodinated nanoparticle contrast agents from lymph nodes can be modulated by changes in the structure of the agent itself. Using the same agent, smaller particles deliver material to the lymph nodes more quickly and clear more quickly.
引用
收藏
页码:91 / 96
页数:6
相关论文
共 19 条
[1]  
BACON ER, 1994, Patent No. 5322679
[2]  
BACON ER, 1994, Patent No. 5346688
[3]  
BACON ER, 1993, Patent No. 5264610
[4]   PARTICLE SIZING AND BIOKINETICS OF INTERSTITIAL LYMPHOSCINTIGRAPHIC AGENTS [J].
BERGQVIST, L ;
STRAND, SE ;
PERSSON, BRR .
SEMINARS IN NUCLEAR MEDICINE, 1983, 13 (01) :9-19
[5]  
CHRISTY NM, 1992, P INT S CONTR REL BI, V19, P355
[6]   INDIRECT LYMPHOGRAPHY WITH PERFLUBRON EMULSION - PRECLINICAL AND CLINICAL-RESULTS [J].
HANNA, G ;
HOPKINS, R ;
FLAIM, K ;
LEESE, P ;
SCHMIDSCHONBEIN, G ;
WOLF, GL .
INVESTIGATIVE RADIOLOGY, 1994, 29 :S33-S35
[7]   INTRACELLULAR AND EXTRACELLULAR TRANSPORT OF PERFLUORO CARBON EMULSION FROM SUBCUTANEOUS TISSUE TO REGIONAL LYMPHATICS [J].
IKOMI, F ;
HANNA, G ;
SCHMIDSCHONBEIN, GW .
ARTIFICIAL CELLS BLOOD SUBSTITUTES AND BIOTECHNOLOGY, 1994, 22 (04) :1441-1447
[8]   MECHANISM OF COLLOIDAL PARTICLE UPTAKE INTO THE LYMPHATIC-SYSTEM - BASIC STUDY WITH PERCUTANEOUS LYMPHOGRAPHY [J].
IKOMI, F ;
HANNA, GK ;
SCHMIDSCHONBEIN, GW .
RADIOLOGY, 1995, 196 (01) :107-113
[9]  
Liversidge G.G., 1992, USP Pat, Patent No. [5145684, US5145684]
[10]  
Liversidge GG, 1994, Patent No. [U. S. Patent 5,318,767, 5318767]